Remembering Longtime Community Leader, Lee Herron

Remembering Longtime Community Leader, Lee Herron

Georgia Bio Members & Partners:
 
It is with a heavy heart that I share with you the sad news that Georgia has lost one of its long-time innovation and entrepreneurship champions with the passing of Dr. Lee Herron last Friday, July 12.



Lee was a dear friend, colleague, mentor, and irreplaceable leader within our community. He retired from Georgia Research Alliance (GRA) in spring 2024 after a 16-year career with the Alliance. Most recently, Lee led GRA’s agricultural technology programs including the Greater Yield initiative. He directed its award-winning venture development program for 15 years, which helped to launch 200+ university-based companies that attracted more than $2 billion in equity investment. A seasoned executive, Lee harnessed his 20 years of entrepreneurial experience to help startups develop sound business strategies. Prior to joining GRA, Lee managed the biosciences division of Georgia Tech’s Advanced Technology Development Center (ATDC), advising early-stage life science companies. Lee served in many community leadership capacities including on the boards of Georgia Bio, Southeast Life Sciences, the Global Center for Medical Innovation’s Industry Advisory Board, the Biolocity Oversight Committee and the NSF Center for Cell Manufacturing Technology’s Commercialization Advisory Board.

I am at a loss to even estimate the vast impact he has had on so many of us not only in a business capacity but also as a wise and caring leader whose warmth and humanity characterized every interaction with him. I encourage you to read the moving tributes from GRA here, and his protégé, Ashley Cornelison’s LinkedIn post here. For those that did not know Lee, these tributes help to paint the picture of a brilliant and kind man who will leave an indelible mark on many across our industry. 

On a personal note, Lee has been a mentor, sounding board, and friend throughout my 18 years at Georgia Bio. A regular volunteer with Georgia Bio for over 2 decades, Lee would provide his feedback on nominees for our annual awards without hesitation and with his trademark candor; he always jumped to help the organization build its network; and served in various leadership capacities including as chair for our Life Sciences Summit in 2017 (pictured). At the same time, he would remember to ask me about my daughter and remind me to take care of myself. Lee enjoyed and excelled at connecting with people, and his health challenges rarely slowed him down. In looking at my last texts with him from mid-May, he was still committing to providing feedback on our Golden Helix Award nominees and suggesting he introduce me to one of his industry colleagues. I am truly heartbroken. His honesty, humor, and guidance on a personal and professional level will be missed.
 
Lee was an early recipient of Georgia Bio’s highest honor, the Industry Growth Fellow Award in 2008. Georgia Bio will honor Lee and his legacy at this year’s Georgia Life Sciences Summit on October 22.
 
Please continue sending your thoughts and prayers for Lee’s wife Rita and the Herron family.

A memorial service will take place this Thursday, July 18. More here.
 
With heartfelt sympathy,


Maria
President & CEO
Georgia Bio

Legal Experts Signal Continued Uncertainty for Life Sciences M&A

By Maria Thacker Goethe • October 22, 2025
“Evolving FTC and DOJ policies leave investors and innovators navigating a cautious M&A landscape

Georgia Life Sciences Launches New Podcast Series, Vitals, in Partnership with Cloudcast Media

October 6, 2025
Atlanta, GA — October 6 — Georgia Life Sciences today announced the launch of Vitals, a new podcast series developed in partnership with Cloudcast Media, a leader in branded podcast production. The series will spotlight the people, ideas, and innovations shaping the future of Georgia’s rapidly growing life sciences sector. Hosted by Georgia Life Sciences’ CEO, Maria Thacker Goethe, Vitals will feature in-depth conversations with scientists, entrepreneurs, investors, educators, policymakers, and patient advocates. Each episode will explore the challenges and opportunities facing Georgia’s life sciences ecosystem—spanning biopharma, medical technology, digital health, and advanced manufacturing. “Vitals gives us a powerful platform to showcase the remarkable work happening within our state,” said Maria Thacker Goethe. “By sharing these stories, we’re highlighting not only groundbreaking science but also the collaboration and talent that make Georgia such a vibrant hub for health innovation.” Cloudcast Media, known for its expertise in storytelling and high-quality podcast production, will bring industry insights and technical support to ensure the series reaches audiences across Georgia and beyond. “We’re proud to partner with Georgia Life Sciences on Vitals,” said Charles Parisi, Founder and CEO of Cloudcast. “This series will elevate the voices of innovators who are advancing science, improving patient outcomes, and building Georgia’s reputation as a global life sciences leader. We are very excited that Cloudcast Atlanta can play a role in supporting Maria and the impactful work of Georgia Life Sciences.” The first episode of Vitals launched today and is available on Apple Podcasts, Spotify, and other major streaming platforms, as well as through the Georgia Life Sciences website.

BIO Statement on Most Favored Nation Policies

October 1, 2025
September 30, 2025 WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on Most Favored Nation policies: "For too many years, Americans have subsidized the research and development necessary to bring newer and better medicines to patients around the world. As we saw with defense spending and NATO, the solution is not to weaken a strategically important American industry, but for other countries to pay their fair share. “Today’s announcement in the Oval Office highlights the problems with a drug delivery system where half of the cost of innovative medicines goes to middlemen and distributors, and where the supply chain distorts prices paid by the American people. We support a new framework that addresses the cost of medicines by simplifying the system - and making medicines directly available to patients. “But importing socialist price controls through most-favored nation policies fundamentally does not address the imbalance in international pricing for innovative medicines. MFN will not lower the out-of-pocket prices that most Americans pay for medicines. Even worse, it will jeopardize the entrepreneurial spirit and deter the capital necessary for a vibrant and essential American biotechnology industry to thrive and may cause most harm to small and midsize biotech companies, which are responsible for discovering more than half of all new treatments. “Without these biotech innovators and a free-market system, we risk slower scientific progress, decreased access to new medicines, compromised national security, fewer American jobs and perhaps most tragically, a diminished hope for those suffering with illness and disease. There are much better ways to address this problem than MFN.” ###
MORE POSTS